DaVita HealthCare Partners Inc. (NYSE:DVA) was upgraded by analysts at Raymond James Financial Inc. from a “market perform” rating to an “outperform” rating in a report released on Tuesday. The firm currently has a $75.00 target price on the stock. Raymond James Financial Inc.’s price objective would suggest a potential upside of 13.93% from the company’s current price.

Several other research firms have also weighed in on DVA. Bank of America Corp. lowered shares of DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 price objective for the company. in a research note on Tuesday, September 6th. TheStreet lowered shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research note on Monday, August 8th. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Citigroup Inc. initiated coverage on shares of DaVita HealthCare Partners in a research note on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 price objective for the company. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Saturday, June 4th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. DaVita HealthCare Partners presently has a consensus rating of “Hold” and an average price target of $76.36.

Shares of DaVita HealthCare Partners (NYSE:DVA) opened at 65.83 on Tuesday. The firm has a 50-day moving average of $66.83 and a 200-day moving average of $73.13. The firm has a market cap of $13.62 billion, a PE ratio of 38.30 and a beta of 1.07. DaVita HealthCare Partners has a 52 week low of $61.36 and a 52 week high of $78.94.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.03. DaVita HealthCare Partners had a net margin of 2.51% and a return on equity of 16.48%. The firm earned $3.72 billion during the quarter, compared to analyst estimates of $3.67 billion. During the same quarter last year, the business earned $0.95 EPS. The company’s revenue was up 8.2% compared to the same quarter last year. On average, analysts expect that DaVita HealthCare Partners will post $3.76 EPS for the current year.

In related news, insider Jeanine Marie Jiganti sold 1,291 shares of the business’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $78.51, for a total value of $101,356.41. Following the transaction, the insider now directly owns 5,716 shares of the company’s stock, valued at approximately $448,763.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael David Staffieri sold 20,262 shares of the business’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the completion of the transaction, the chief operating officer now directly owns 52,279 shares in the company, valued at $3,821,072.11. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Nomura Asset Management Co. Ltd. increased its stake in DaVita HealthCare Partners by 43.6% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 47,755 shares of the company’s stock valued at $3,329,000 after buying an additional 14,500 shares during the period. Norges Bank acquired a new stake in DaVita HealthCare Partners during the fourth quarter valued at approximately $135,225,000. Chevy Chase Trust Holdings Inc. increased its stake in DaVita HealthCare Partners by 3.8% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 139,937 shares of the company’s stock valued at $10,269,000 after buying an additional 5,152 shares during the period. DnB Asset Management AS increased its stake in DaVita HealthCare Partners by 81.3% in the first quarter. DnB Asset Management AS now owns 18,510 shares of the company’s stock valued at $1,358,000 after buying an additional 8,300 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in DaVita HealthCare Partners by 13.0% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 38,786 shares of the company’s stock valued at $2,846,000 after buying an additional 4,456 shares during the period. 83.55% of the stock is currently owned by institutional investors.

DaVita HealthCare Partners Company Profile

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.